Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore Pharma receives gross proceeds of SEK 200 million.
The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. Vicore Pharma intends to use the issue proceeds to finance preparations for Phase 2b trial in idiopathic pulmonary fibrosis (IPF) including scale-up and manufacturing whilst continuing and completing the IPF AIR trial.
Vinge’s team has consisted of Rikard Lindahl, Joel Magnusson and Annie Fällström.
